THE LAW / WHAT FDA HAS SAID
Wolverine Legal Status remains unsettled
BPC-157 TB-500 left Category 2, an FDA warning list, after both requests were pulled. That change didn't approve either substance.
Wolverine legal status is unsettled, not approved
BPC-157 and TB-500 were made for research, not cleared as drugs. That's the first fact behind Wolverine legal status.
FDA hasn't approved either substance to treat people. No medical use of the blend has FDA clearance.
FDA last changed its page on April 22, 2026. Neither substance now appears in Category 2, a warning list for drugs that may pose safety risks.
The requests were pulled, but FDA left its safety concerns on the page. A pulled request isn't an approval.
BPC-157 entered Category 2 on September 29, 2023. FDA warned about immune reactions and unwanted matter in the product.
Thymosin beta-4, the small part also called TB-500, entered Category 2 on September 29, 2023 too. FDA said key safety facts were missing.
Pulling both requests ended those Category 2 entries. FDA still hasn't told pharmacies what to do next.
That leaves access through a pharmacy that makes a drug for one patient unclear [14][15]. The change isn't a green light.
The list changed, but your access is not settled, and anyone promising you a simple legal path is saying more than FDA has said about your care.
A July meeting ended without a public answer
FDA put both forms of BPC-157 and both forms of TB-500 on a meeting list. The meeting ran July 23-24, 2026 [16].
The group was asked whether pharmacies could use the raw substances in made-to-order drugs. Its advice couldn't become a rule by itself.
After hearing the group, FDA makes its decision [14]. A meeting date doesn't grant approval.
FDA staff had said neither substance ought to be added. By September 2026, the agency hadn't posted the group's votes.
The answer hasn't changed. BPC-157 and TB-500 were discussed, but no final vote appears in the public record.
You can't guess a lawful path from an unfinished review. Until FDA acts, you and your pharmacy are left without a clear answer.
CLINICAL ROUTE / INDIVIDUAL REVIEW
A calendar entry is not a prescribing decision
The unresolved status keeps retail availability outside this ledger. At Promise Peptides (mypromise.com), a licensed clinician may prescribe Wolverine (research blend) only after evaluating the individual patient and confirming a lawful route; the calendar entry above is no substitute for that decision.
A special-order pharmacy still needs a lawful reason
The law has two main paths for drugs made outside normal factories, and the first begins with a review of one named patient's need. A licensed pharmacy or doctor may then make the drug.
A second path lets sites registered with FDA prepare larger batches [14]. Those sites face a different set of checks.
For medicine prepared for a named patient, the prescriber begins with a real visit. The visit may be in person or through lawful telehealth.
If the drug fits that person's care, the prescriber writes a valid order. With a valid order, a state-licensed pharmacy can make and give out the drug [14].
Telehealth doesn't change which ingredients the law allows. A real visit and valid order are still needed.
The maker must follow the right legal path for each ingredient [14]. FDA hasn't said how a pulled Category 2 request affects that choice.
This is broad information, not medical or legal advice. Neither substance is offered on this page.
No Wolverine use has FDA approval
BPC-157 and TB-500 aren't FDA-approved drugs. Their requests left the Category 2 warning table after both were pulled [14][15].
FDA kept its safety notes and hasn't told drug makers what comes next. Thymosin beta-4 and both substances are also barred in tested sport.
BPC-157 access through a special-order pharmacy is unclear
FDA put BPC-157 in Category 2 on September 29, 2023. Its April 22, 2026 page shows the request was later pulled.
The July 23-24, 2026 meeting list also named BPC-157 for possible pharmacy use [14][16]. FDA staff opposed adding it, and no vote has been posted.
FDA looks at each substance, not the blend
The blend has no standing of its own. FDA looks at BPC-157 and the Thymosin beta-4 piece called TB-500 one by one.
Both entered Category 2 in September 2023. An FDA page from April 22, 2026 says both requests were then pulled.
The July 2026 meeting list included both for possible pharmacy use. The group’s votes are still missing from FDA’s public page [14][15][16].
FDA hasn't approved either substance, and sport bans both
FDA hasn't approved BPC-157 or TB-500 to treat anyone. Both entered Category 2 in 2023 [14][15].
FDA kept its safety concerns after the requests were pulled. Tested sport bars BPC-157 as an unapproved drug and bars TB-500 under rules for growth drugs [8].
Your prescriber and your pharmacy each have duties under the law. A web visit can't erase those duties or make a barred drug lawful for you.